117 related articles for article (PubMed ID: 11367160)
1. Second-generation drugs fight resistant virus.
STEP Perspect; 1999; 99(1):3. PubMed ID: 11367160
[TBL] [Abstract][Full Text] [Related]
2. New nonnucleoside reverse transcriptase inhibitors.
GMHC Treat Issues; 1999 Feb; 13(2):10. PubMed ID: 11366114
[TBL] [Abstract][Full Text] [Related]
3. Preliminary pharmacokinetic data on ABT-378 encouraging.
AIDS Patient Care STDS; 1998 Feb; 12(2):146. PubMed ID: 11361913
[No Abstract] [Full Text] [Related]
4. Impact of HIV protease inhibitor resistance in treatment-naive populations in the united states.
Hicks C
AIDS Read; 2005 Dec; 15(12):683-6, 689-90. PubMed ID: 16355598
[TBL] [Abstract][Full Text] [Related]
5. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies.
Erickson JW; Gulnik SV; Markowitz M
AIDS; 1999; 13 Suppl A():S189-204. PubMed ID: 10885776
[No Abstract] [Full Text] [Related]
6. New drugs for old.
Winston A; Stebbing J
J HIV Ther; 2005 Mar; 10(1):11-6. PubMed ID: 15951729
[TBL] [Abstract][Full Text] [Related]
7. Invirase and cross resistance.
AIDS Patient Care; 1995 Oct; 9(5):256. PubMed ID: 11361409
[No Abstract] [Full Text] [Related]
8. Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
Sabin CA; Wilkins E; Murphy M; Fisher M; de Ruiter A; Easterbrook PJ; Leen C; Vlahakis E; Cane PA; Li X; Pillay D;
Antivir Ther; 2003 Aug; 8(4):301-8. PubMed ID: 14518699
[TBL] [Abstract][Full Text] [Related]
9. Anti-HIV therapies early in the pipeline.
Bartnof HS
BETA; 1999; 12(4):57. PubMed ID: 11367256
[TBL] [Abstract][Full Text] [Related]
10. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
11. Drug watch.
Whitson S
Posit Aware; 1999; 10(3):16-7. PubMed ID: 11366758
[TBL] [Abstract][Full Text] [Related]
12. HIV protease inhibitors.
Winslow DL; Otto MJ
AIDS; 1995; 9 Suppl A():S183-92. PubMed ID: 8819585
[No Abstract] [Full Text] [Related]
13. ICAAC: new drugs in late breaker session.
James JS
AIDS Treat News; 1999 Oct; (No 328):3-5. PubMed ID: 11366817
[TBL] [Abstract][Full Text] [Related]
14. The younger generation.
Jefferys R; Forataro K
Body Posit; 1999 Aug; 12(8):15-6. PubMed ID: 11367065
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV-1-infected patients: a French nationwide study.
Masquelier B; Costagliola D; Schmuck A; Cottalorda J; Schneider V; Izopet J; Calvez V; Descamps D; Poggi C; Brun-Vézinet F;
J Med Virol; 2005 Aug; 76(4):441-6. PubMed ID: 15977249
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 protease inhibitors: effects on HIV-2 replication and resistance.
Menéndez-Arias L; Tözsér J
Trends Pharmacol Sci; 2008 Jan; 29(1):42-9. PubMed ID: 18054799
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological exposure and the development of drug resistance in HIV.
Hoetelmans R
Antivir Ther; 2001; 6 Suppl 2():37-47. PubMed ID: 11678477
[No Abstract] [Full Text] [Related]
18. Transmitted multidrug resistant HIV-1: new and investigational therapeutic approaches.
Shet A; Markowitz M
Curr Opin Investig Drugs; 2006 Aug; 7(8):709-20. PubMed ID: 16955682
[TBL] [Abstract][Full Text] [Related]
19. Genotypic resistance tests for the clinical management of patients with primary HIV infection.
Narciso P; Lazzarin A
Scand J Infect Dis Suppl; 2003; 106():66-70. PubMed ID: 15000588
[TBL] [Abstract][Full Text] [Related]
20. Aspects of successful drug discovery and development.
Pauwels R
Antiviral Res; 2006 Sep; 71(2-3):77-89. PubMed ID: 16828174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
